Broad availability of low-cost generic pre-exposure prophylaxis drugs could significantly reduce 340B covered entities' revenues on billings for PrEP. | Shutterstock

Much Cheaper PrEP Drugs Could Mean Financial Upheaval for 340B Covered Entities

In Pharma IndustryMay 25, 2021677 Views

Ron Shinkman

While an important drug’s introduction into the generic market is often celebrated by both providers and patients, generic pre-exposure prophylaxis drugs (PrEP) for patients at risk of contracting HIV could prove a financial disaster for some 340B covered entities.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Ron Shinkman

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden

*Sign up for news summaries and alerts from 340B Report